Benzinga · Jul 17, 2026
What's Going On With SANUWAVE Health Stock On Friday?
NASDAQ:SNWV shares are trading down 0.5% in premarket as SANUWAVE Health beats Q2 revenue expectations, but faces financial constraints and competition.
SN
NASDAQ · SNWV
SANUWAVE Health, Inc.
Healthcare · Medical - Devices
$4.66
Down-$0.04 (-0.75%)
Updated Aug 28, 2026, 5:18 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 270.06M
- P/E ratio
- -38.33
- Dividend yield
- 0.00%
- 52-week range
- $4.50 – $44.94
- Volume
- 45.06K
- Avg. volume
- 113.39K
Price performance
SNWV price history
1M range · 0 trading sessions · Daily adjusted prices
SNWV does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest SNWV news
The latest Smart Investors Daily articles mentioning SNWV.
Stock researchCompany · Overview
SNWV research
Overview
Company profile and research snapshot.
Company profile
SANUWAVE Health Inc is an ultrasound and shock wave technology company using patented systems of noninvasive, high-energy, acoustic shock waves or low-intensity and non-contact ultrasound for regenerative medicine and other applications. The company's focus is regenerative medicine utilizing noninvasive, acoustic shock waves or ultrasound to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's two primary systems are UltraMIST and PACE. UltraMIST and PACE are the only two Food and Drug Administration (FDA) approved directed energy systems for wound healing.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $54.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 30, 2026 | Roth Capital | Buy | — |
| Sep 3, 2025 | Northland Capital Markets | Outperform | — |
| Aug 22, 2025 | Roth Capital | Buy | — |
| Jul 29, 2025 | Roth Capital | Buy | — |
| Sep 15, 2020 | Lake Street | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 27, 2026
Sanuwave: A Compelling Asymmetric Opportunity In Advanced Wound Care
Sanuwaveâs growth prospects are defined by a massive TAM and a historic regulatory tailwind that is currently dismantling its primary competition. Read more here.
SeekingAlpha · Jan 15, 2026
Infuse Asset Management Q4 2025 Letter
Nu Holdings' traction in Mexico after receiving the full banking license is evidence that the model is replicable in geographies outside of Brazil. Read more here.
GlobeNewswire Inc. · Dec 10, 2025
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Sanuwave Health, a wound care products company, will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026, offering meetings with company management.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
